Novartis discontinues ALS drug trial after failure
Bloomberg News reports Novartis discontinued development of an experimental ALS medicine after a mid-stage trial failed to show it worked better than a dummy drug in delaying disease.
Novartis BX:NOT halted development of an experimental drug it had hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig's disease, Bloomberg News reported on Wednesday. The mid-stage trial was discontinued after the medicine failed to show it worked better than a dummy drug in delaying disease.